Utilizzo del levetiracetam in 46 pazienti Italiani in età pediatrica

Translated title of the contribution: Use of levetiracetam in refractory pediatric epilepsy. An Italian study on 46 patients

P. Avantaggiato, A. Romeo, G. Capovilla, R. Cusmai, F. Beccaria, M. Viri, M. Lodi, E. Alfei, P. Veggiotti

Research output: Contribution to journalArticle

Abstract

Levetiracetam is one of the newer-generation antiepilepsy drugs and it has been demonstrated to be effective, as add-on therapy, on partial seizures in adults and potentially also on generalized ones. Considering its favorable pharmacokinetic and the absence of adverse events, it has been recently used also in children. We have treated 46 patients (range 4-16 yrs; mean 11.1 yrs) with LVT as add-on therapy for up to 20 months. All patients were affected by refractory epilepsy, taking from 1 to 4 AEDs, and with a documented lack of efficacy of at least 3 other previously taken AEDs. LVT was effective in reducing seizure frequency (11 patients, 23,9%), especially in case of symptomatic partial epilepsy and generalized epilepsy. We noticed that the range of the effective dose (11-33 mg/Kg/die) was below the value reported in literature (20-40 mg/Kg/die). Side-effects were presented in 13 patients (28,2%), leading to interruption of treatment in only 1 case. No evidence was found about major efficacy on a specific type of seizure.

Original languageItalian
Pages (from-to)93-95
Number of pages3
JournalBollettino - Lega Italiana contro l'Epilessia
Issue number121-122
Publication statusPublished - Jul 2003

Fingerprint

etiracetam
Epilepsy
Pediatrics
Seizures
Generalized Epilepsy
Partial Epilepsy
Therapeutics
Pharmacokinetics

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Avantaggiato, P., Romeo, A., Capovilla, G., Cusmai, R., Beccaria, F., Viri, M., ... Veggiotti, P. (2003). Utilizzo del levetiracetam in 46 pazienti Italiani in età pediatrica. Bollettino - Lega Italiana contro l'Epilessia, (121-122), 93-95.

Utilizzo del levetiracetam in 46 pazienti Italiani in età pediatrica. / Avantaggiato, P.; Romeo, A.; Capovilla, G.; Cusmai, R.; Beccaria, F.; Viri, M.; Lodi, M.; Alfei, E.; Veggiotti, P.

In: Bollettino - Lega Italiana contro l'Epilessia, No. 121-122, 07.2003, p. 93-95.

Research output: Contribution to journalArticle

Avantaggiato, P, Romeo, A, Capovilla, G, Cusmai, R, Beccaria, F, Viri, M, Lodi, M, Alfei, E & Veggiotti, P 2003, 'Utilizzo del levetiracetam in 46 pazienti Italiani in età pediatrica', Bollettino - Lega Italiana contro l'Epilessia, no. 121-122, pp. 93-95.
Avantaggiato P, Romeo A, Capovilla G, Cusmai R, Beccaria F, Viri M et al. Utilizzo del levetiracetam in 46 pazienti Italiani in età pediatrica. Bollettino - Lega Italiana contro l'Epilessia. 2003 Jul;(121-122):93-95.
Avantaggiato, P. ; Romeo, A. ; Capovilla, G. ; Cusmai, R. ; Beccaria, F. ; Viri, M. ; Lodi, M. ; Alfei, E. ; Veggiotti, P. / Utilizzo del levetiracetam in 46 pazienti Italiani in età pediatrica. In: Bollettino - Lega Italiana contro l'Epilessia. 2003 ; No. 121-122. pp. 93-95.
@article{ff9f567ff3e8448bbd281c8e3098f16b,
title = "Utilizzo del levetiracetam in 46 pazienti Italiani in et{\`a} pediatrica",
abstract = "Levetiracetam is one of the newer-generation antiepilepsy drugs and it has been demonstrated to be effective, as add-on therapy, on partial seizures in adults and potentially also on generalized ones. Considering its favorable pharmacokinetic and the absence of adverse events, it has been recently used also in children. We have treated 46 patients (range 4-16 yrs; mean 11.1 yrs) with LVT as add-on therapy for up to 20 months. All patients were affected by refractory epilepsy, taking from 1 to 4 AEDs, and with a documented lack of efficacy of at least 3 other previously taken AEDs. LVT was effective in reducing seizure frequency (11 patients, 23,9{\%}), especially in case of symptomatic partial epilepsy and generalized epilepsy. We noticed that the range of the effective dose (11-33 mg/Kg/die) was below the value reported in literature (20-40 mg/Kg/die). Side-effects were presented in 13 patients (28,2{\%}), leading to interruption of treatment in only 1 case. No evidence was found about major efficacy on a specific type of seizure.",
keywords = "Levetiracetam, Pediatric Epilepsy",
author = "P. Avantaggiato and A. Romeo and G. Capovilla and R. Cusmai and F. Beccaria and M. Viri and M. Lodi and E. Alfei and P. Veggiotti",
year = "2003",
month = "7",
language = "Italian",
pages = "93--95",
journal = "Bollettino - Lega Italiana contro l'Epilessia",
issn = "0394-560X",
publisher = "Lega Italiana contro l'Epilessia",
number = "121-122",

}

TY - JOUR

T1 - Utilizzo del levetiracetam in 46 pazienti Italiani in età pediatrica

AU - Avantaggiato, P.

AU - Romeo, A.

AU - Capovilla, G.

AU - Cusmai, R.

AU - Beccaria, F.

AU - Viri, M.

AU - Lodi, M.

AU - Alfei, E.

AU - Veggiotti, P.

PY - 2003/7

Y1 - 2003/7

N2 - Levetiracetam is one of the newer-generation antiepilepsy drugs and it has been demonstrated to be effective, as add-on therapy, on partial seizures in adults and potentially also on generalized ones. Considering its favorable pharmacokinetic and the absence of adverse events, it has been recently used also in children. We have treated 46 patients (range 4-16 yrs; mean 11.1 yrs) with LVT as add-on therapy for up to 20 months. All patients were affected by refractory epilepsy, taking from 1 to 4 AEDs, and with a documented lack of efficacy of at least 3 other previously taken AEDs. LVT was effective in reducing seizure frequency (11 patients, 23,9%), especially in case of symptomatic partial epilepsy and generalized epilepsy. We noticed that the range of the effective dose (11-33 mg/Kg/die) was below the value reported in literature (20-40 mg/Kg/die). Side-effects were presented in 13 patients (28,2%), leading to interruption of treatment in only 1 case. No evidence was found about major efficacy on a specific type of seizure.

AB - Levetiracetam is one of the newer-generation antiepilepsy drugs and it has been demonstrated to be effective, as add-on therapy, on partial seizures in adults and potentially also on generalized ones. Considering its favorable pharmacokinetic and the absence of adverse events, it has been recently used also in children. We have treated 46 patients (range 4-16 yrs; mean 11.1 yrs) with LVT as add-on therapy for up to 20 months. All patients were affected by refractory epilepsy, taking from 1 to 4 AEDs, and with a documented lack of efficacy of at least 3 other previously taken AEDs. LVT was effective in reducing seizure frequency (11 patients, 23,9%), especially in case of symptomatic partial epilepsy and generalized epilepsy. We noticed that the range of the effective dose (11-33 mg/Kg/die) was below the value reported in literature (20-40 mg/Kg/die). Side-effects were presented in 13 patients (28,2%), leading to interruption of treatment in only 1 case. No evidence was found about major efficacy on a specific type of seizure.

KW - Levetiracetam

KW - Pediatric Epilepsy

UR - http://www.scopus.com/inward/record.url?scp=1242340301&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1242340301&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:1242340301

SP - 93

EP - 95

JO - Bollettino - Lega Italiana contro l'Epilessia

JF - Bollettino - Lega Italiana contro l'Epilessia

SN - 0394-560X

IS - 121-122

ER -